These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 10733167

  • 1. Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus-infected endothelial cells: role of MHC class I antigens.
    Weinberg A, Zhang L, Hayward AR.
    Viral Immunol; 2000; 13(1):37-47. PubMed ID: 10733167
    [Abstract] [Full Text] [Related]

  • 2. NK recognition of cytomegalovirus-infected endothelial cells depends on viral replication and MHC class I expression.
    Weinberg A, Zhang L, Tuder RM.
    Viral Immunol; 1996; 9(2):131-40. PubMed ID: 8822629
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus (CMV)-specific lysis of CMV-infected target cells can be mediated by both NK-like and virus-specific cytotoxic T lymphocytes.
    Gehrz RC, Rutzick SR.
    Clin Exp Immunol; 1985 Jul; 61(1):80-9. PubMed ID: 2994924
    [Abstract] [Full Text] [Related]

  • 4. Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus-activated T cells.
    Waldman WJ, Knight DA.
    Am J Pathol; 1996 Jan; 148(1):105-19. PubMed ID: 8546198
    [Abstract] [Full Text] [Related]

  • 5. [Immune reaction to human cytomegalovirus].
    Ito M.
    Nihon Rinsho; 1998 Jan; 56(1):62-8. PubMed ID: 9465666
    [Abstract] [Full Text] [Related]

  • 6. HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells.
    Lindsley MD, Torpey DJ, Rinaldo CR.
    J Immunol; 1986 Apr 15; 136(8):3045-51. PubMed ID: 2420881
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques.
    Kaur A, Daniel MD, Hempel D, Lee-Parritz D, Hirsch MS, Johnson RP.
    J Virol; 1996 Nov 15; 70(11):7725-33. PubMed ID: 8892893
    [Abstract] [Full Text] [Related]

  • 8. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG, Sun Q, Burton RL, Tilden A, Vaughan WP, Carabasi M, Salzman D, Ship A.
    Hum Gene Ther; 2000 Jul 01; 11(10):1453-63. PubMed ID: 10910142
    [Abstract] [Full Text] [Related]

  • 9. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
    Romagnani C, Pietra G, Falco M, Mazzarino P, Moretta L, Mingari MC.
    Hum Immunol; 2004 May 01; 65(5):437-45. PubMed ID: 15172443
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro.
    Muraoka S.
    Eur J Immunol; 1991 Sep 01; 21(9):2095-103. PubMed ID: 1679712
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Induction of cytomegalovirus-specific CD4+ cytotoxic T lymphocytes from seropositive or negative healthy subjects or stem cell transplant recipients.
    Tazume K, Hagihara M, Gansuvd B, Higuchi A, Ueda Y, Hirabayashi K, Hojo M, Tanabe A, Okamoto A, Kato S, Hotta T.
    Exp Hematol; 2004 Jan 01; 32(1):95-103. PubMed ID: 14725906
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro induction of endothelial HLA class II antigen expression by cytomegalovirus-activated CD4+ T cells.
    Waldman WJ, Knight DA, Adams PW, Orosz CG, Sedmak DD.
    Transplantation; 1993 Dec 01; 56(6):1504-12. PubMed ID: 7904091
    [Abstract] [Full Text] [Related]

  • 19. Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease.
    Odendahl M, Grigoleit GU, Bönig H, Neuenhahn M, Albrecht J, Anderl F, Germeroth L, Schmitz M, Bornhäuser M, Einsele H, Seifried E, Busch DH, Tonn T.
    Cytotherapy; 2014 Sep 01; 16(9):1245-56. PubMed ID: 25108651
    [Abstract] [Full Text] [Related]

  • 20. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.
    McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR.
    J Med Virol; 1994 May 01; 43(1):103-10. PubMed ID: 8083644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.